The NDA acceptance and absence of an AdCom are modest positives that de-risk the regulatory path, but the PDUFA date is nearly 10 months out. Traders should monitor for any FDA review updates or clinical data releases ahead of May 2027. The stock's historical neutral filings have underperformed, so near-term upside may be limited until a clearer catalyst emerges.
Drug in focus
AXSM drug pipeline →AXS-12
● Neutral Named in this press release- Impact
- Phase
- Filed/PDUFA (NDA accepted; Phase 3 completed)
- Time to market
- NDA is already under FDA review; a decision is due by May 1, 2027, with commercial launch in 2027 if approved — roughly 9 months to the binary.
- Next catalyst
- PDUFA date · May 1, 2027 165d
What to watchWatch for FDA communications ahead of the May 1, 2027 PDUFA, e.g., any newly scheduled advisory committee, labeling discussions, or a potential priority-review/timing change, and treat AXS-12 approval as incremental upside on top of the AUVELITY (incl. Alzheimer's agitation) and SUNOSI commercial story rather than the stock's primary thesis. Near-term share moves are more likely tied to quarterly product sales and the Alzheimer's agitation launch than to AXS-12, since its binary is ~9 months out.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 15 $237.53entry
- T+1 · 4mo ago −0.21%α +0.34% · $237.04
- T+5 · 4mo ago +0.88%α +1.86% · $239.62
- T+20 · 3mo ago −9.63%α −11.97% · $214.66
- T+60 · 6w ago −28.40%α −30.93% · $170.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting, which reduces regulatory uncertainty. This is a procedural milestone for a mid-stage pipeline asset, not a revenue-generating event, and the stock's historical reaction to neutral filings has been negative on average.
Key Facts
- FDA accepted NDA filing for AXS-12 (reboxetine) to treat cataplexy in narcolepsy
- PDUFA target action date set for May 1, 2027
- FDA indicated no advisory committee meeting is currently planned
- AXS-12 has Orphan Drug Designation for narcolepsy
- Cataplexy affects an estimated 70% of narcolepsy patients
Financial Impact
No financial terms disclosed; AXS-12 is not yet approved and has no revenue. Orphan drug designation provides market exclusivity potential if approved.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) at the PDUFA date
- AXS-12 is not yet approved and has no commercial revenue
- Long timeline to PDUFA (May 2027) leaves room for negative developments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3327580 |
Track record
26 reports on AXSM
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Viewing Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers